Dengue vaccine: a key for prevention

References

• Thisyakorn U, Thisyakorn C. Dengue: global threat. Southeast Asian J Trop Med Public Health. 2015;46(Suppl. 1):3–10.
   PubMedGoogle Scholar
• Alirol E, Getaz L, Stoll B, et al. Urbanisation and infectious diseases in a globalized world. Lancet Infect Dis. 2011;10:131–141.
   Google Scholar
• Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–507.
   PubMed Web of Science ®Google Scholar
• Shepard DS, Undurraga EA, Halasa YA. Economic and disease burden of dengue in Southeast Asia. PLos Negl Trop Dis. 2013;7:e2055.
   PubMed Web of Science ®Google Scholar
• Thisyakorn U, Thisyakorn C. Changing epidemiology of dengue in Asia Pacific. In: Srisawat N, Jaimchariyatam N, Tantawichien T, et al., editors. Dengue. Bangkok: Text and Journal Publication Limited; 2019. p. 5–7.
   Google Scholar
• World Health Organization. Dengue hemorrhagic fever; diagnosis, treatment, prevention and control. 2nd ed. Geneva: World Health Organization; 1997.
   Google Scholar
• Guidelines WHO. Approved by the guidelines review committee. dengue guidelines for diagnosis, treatment, prevention and control. New ed. Geneva: World Health Organization; 2009.
   Google Scholar
• Horstick O, Runge-Ranzinger S. Dengue case classification. In: Srisawat N, Jaimchariyatam N, Tantawichien T, et al., editors. Dengue. Bangkok: Text and Journal Publication Limited; 2019. p. 93–98.
   Google Scholar
• Tantawichien T, Thisyakorn U. Dengue: an overview. Southeast Asian J Trop Med PublicHealth. 2017;48(Suppl. 1):2–19.
   Google Scholar
• World Health Organization (WHO). Global strategy for dengue prevention and control 2012-2020. Geneva: WHO; 2012.
   Google Scholar
• Horstick O, Boyce R, Runge-Ranzinger S. Dengue vector control: assessing what works? Southeast Asian J Trop Med Public Health. 2017;48(Suppl. 1):181–195.
   Google Scholar
• Thisyakorn U, Thisyakorn C. Prospects for the development of a dengue vaccine. Southeast Asian J Trop Med Public Health. 2017;48(Suppl. 1):196–201.
   Google Scholar
• Thisyakorn U, Thisyakorn C. Dengue vaccine. In: Srisawat N, Jaimchariyatam N, Tantawichien T, et al., editors. Dengue. Bangkok: Text and Journal Publication Limited; 2019. p. 261–267.
   Google Scholar
• McArthur MA, Sztein MB, Edelman R. Dengue vaccines: recent developments, ongoing challenges and current candidates. Expert Rev Vaccines. 2013;12(8):933–953.
   PubMed Web of Science ®Google Scholar
• Thisyakorn U, Thisyakorn C. Latest developments and future directions in dengue vaccines. Ther Adv Vaccine. 2014;2(1):3–9..
   PubMedGoogle Scholar
• Vannice KS, Roehrig JT, Hombach J. Next generation dengue vaccines: a review of the preclinical development pipeline. Vaccine. 2016;33:7091–7099.
   Web of Science ®Google Scholar
• Jongwutiwes S, Putaporntip C, Thisyakorn U. Genetic diversity, phylogenay and evolution of dengue viruses. In: Srisawat N, Jaimchariyatam N, Tantawichien T, et al., editors. Dengue. Bangkok: Text and Journal Publication Limited; 2019. p. 39–81.
   Google Scholar
• Srisawat N, Thisyakorn U, Thisyakorn C. Pathogenesis of dengue virus infection. In: Srisawat N, Jaimchariyatam N, Tantawichien T, et al., editors. Dengue. Bangkok: Text and Journal Publication Limited; 2019. p. 31–37.
   Google Scholar
• Prommalikit O, Thisyakorn U. Dengue virus virulence and diseases severity. Southeast Asian J Trop Med Public Health. 2015;46:(Suppl.1):35–42.
   Google Scholar
• Prommalikit O, Pancharoen C, Nisalak A, et al. Pathogenesis of dengue shock syndrome: immune enhancement or viral virulence. Asian Oceanian J Pediatr Child Health. 2004;3:26–29.
   Google Scholar
• Sabin AB, Schlesinger RW. Production of immunity to dengue with virus modified by propagation in mice. Science. 1945;101(2634):640–642.
   PubMed Web of Science ®Google Scholar
• Dorrance WR, Frankel JW, Gordon I, et al. Clinical and serological response of man to immunization with attenuated dengue and yellow fever viruses. J Immunol. 1956;77(5)::352–64.
   PubMed Web of Science ®Google Scholar
• Bhamarapravati N, Yoksan S, Chayaniyayotin T, et al. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681)-PDK 53; clinical, immunological and biological responses to adult volunteers. Bull World Health Organ. 1987;65(2):189–195.
   PubMed Web of Science ®Google Scholar
• Bhamarapravati N, Yoksan S. Study of bivalent dengue vaccine in volunteers. Lancet. 1989;1(8646):1077.
   PubMed Web of Science ®Google Scholar
• Khan MM, Jiratkanjanakit N, Yoksan S, et al. Infection, dissemination, transmission, and biological attributes of dengue-2 PDK53 candidate vaccine virus after oral infection in Aedes aegypti. AM J Trop Med Hyg. 1994;51(6):864–869.
   PubMed Web of Science ®Google Scholar
• Vaughn DW, Hoke CH, Yoksan S, et al. Tested of dengue2 live-attenuated vaccine (strain 16681 PDK 53) in 10 American volunteers. Vaccine. 1996;14(4):329–336.
   PubMed Web of Science ®Google Scholar
• Dharakul T, Kurane I, Bhamorapravati N, et al. Dengue virus-specific memory T cell responses in human volunteers receiving a live-attenuated dengue virus type 2 candidate vaccine. J Infect Dis. 1994;170(1):27–33.
   PubMed Web of Science ®Google Scholar
• Rupp R, Lukasen GJ, Kirstein JL, et al. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: a phase Ib randomized study. Vaccine. 2015;33(46):6351–6359.
   PubMed Web of Science ®Google Scholar
• Yoksan S. History of Mahidol dengue vaccine. In: Srisawat N, Jaimchariyatam N, Tantawichien T, et al., editors. Dengue. Bangkok: Text and Journal Publication Limited; 2019. p. 9–30.
   Google Scholar
• World Health Organization (WHO). Dengue vaccine. WHO position paper-July 2016. Wkly Epidemiol Rec. 2016;91(30):349–364.
   PubMedGoogle Scholar
• Beck ASB, Barrett ADT. Current status and future prospects of yellow fever vaccines. Expert Rev Vaccines. 2015;14(11):1479–1492.
   PubMed Web of Science ®Google Scholar
• Capeding MR, Tran NH, Hadinegoro SR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children aged 2 to 14 years in Asia: a phase III randomized observer-masked, placebo-controlled trial. Lancet. 2014. 14(384):1358–1365
   Google Scholar
• Villar LA, Rivera-Medina DM, Arredondo-Garcia JL, et al. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year old. Pediatr Infect Dis J. 2013;32(10):1102–1109.
   PubMed Web of Science ®Google Scholar
• Villar LA, Dayan GH, Arredondo-Garcia JL, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015;372(2):113–123.
   PubMed Web of Science ®Google Scholar
• L’Azou M, Moureax A, Sarti E, et al. Symptomatic dengue in children in 10 Asian and Latin American countries. N Engl J Med. 2016;374(12):1155–1166.
   PubMed Web of Science ®Google Scholar
• Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in region of endemic disease. N Engl J Med. 2015;373(13):1195–1206.
   PubMed Web of Science ®Google Scholar
• Schmidt AC, Lin L, Martinez LJ, et al. I randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults in the United States. Am J Trop Med Hyg. 2017;96(6):1325–1337.
   PubMed Web of Science ®Google Scholar
• Prompetchara E, Ketloy C, Keelapang P, et al. Induction of neutralizing antibody response against four dengue vaccines in mice by intramuscular electroporation of tetravalent DNA vaccines. PLoS One. 2014;9:e92643.
   PubMed Web of Science ®Google Scholar
• Thisyakorn U. ADVASC – new regional initiative supporting transition from dengue vaccine to vaccination in Southeast Asia. Vaccine. 2012;30(38):5587–5588.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Dengue vaccine. Wkly Epidemiol Rec. 2016;21:282–284.
   Google Scholar
• Sridhar S, Luedtke A, Langevin M, et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med. 2018;379:327–340.
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Massad E. Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine. Expert Rev Vaccines. 2016;15(4):437–441.
   PubMed Web of Science ®Google Scholar
• Olivera-Botello G, Coudeville L, Fanouillere K, et al. Tetravalent dengue vaccine reduces symptomatic and asymptomatic dengue infections in healthy children and adolescents aged 2-16 years in Asia and Latin America. J Infect Dis. 2016;214(7):994–1000.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Dengue vaccine: WHO position paper-September 2018. Wkly Epidemiol Rec. 2018;93:457–476.
   Google Scholar
• Wilder-Smith A, Smith PG, Luo R, et al. Pre-vaccination screening strategies for the use of the CYD-TDV dengue vaccine: a meeting report. Vaccine. 2019;37(36):S137S46.
   Web of Science ®Google Scholar
• Coudeville L, Baurin N, Shepard DS. The potential impact of dengue vaccination with, and without, pre-vaccination screening. Vaccine. 2019DOI:10.1016//j.vaccine.2019.12.012
   PubMed Web of Science ®Google Scholar
• Biswal S, Reynales H, Saez-Liorens X, et al. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N Engl J Med. 2019;381(21):2009–2019.
   PubMed Web of Science ®Google Scholar
• Biswal S, Borja-Tabora C, Vargas LM, et al. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomized, placebo-controlled, phase 3 trial. www.thelancet.com. Published online March 17, 2020. DOI: https://doi.org/10.1016/50140-6736(20)30414-1.
   Google Scholar
• Whitehead SS. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine. What makes this vaccine different from the Sanofi Pasteur CYDTM vaccine? Expert Rev Vaccines. 2016;13(4):509–517.
   Google Scholar
• Rivino L. T cell immunity to dengue virus and implications for vaccine design. Expert Rev Vaccines. 2016;15(4):443–453.
   PubMed Web of Science ®Google Scholar